Clinical Trials Logo

Advanced Parkinson's Disease clinical trials

View clinical trials related to Advanced Parkinson's Disease.

Filter by:

NCT ID: NCT01723904 Completed - Clinical trials for Advanced Parkinson's Disease

A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease

Start date: October 2012
Phase: Phase 3
Study type: Interventional

This study is to investigate the safety and efficacy of Rotigotine add-on therapy with low doses of Pramipexole or Ropinirole in patients with advanced-stage Parkinson's Disease (PD) who have insufficient response to L-dopa and low doses dopamine receptor agonists.

NCT ID: NCT01536015 Terminated - Clinical trials for Advanced Parkinson's Disease

Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

ROADMAP
Start date: January 2012
Phase: Phase 3
Study type: Interventional

The primary purpose is to demonstrate superiority of Rotigotine over Placebo on motor symptoms when used in subjects with symptoms of Gastrointestinal Dysfunction. Hypothesis: Rotigotine will decrease OFF time compared to Placebo.

NCT ID: NCT01479127 Completed - Clinical trials for Advanced Parkinson's Disease

Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease

Start date: October 2011
Phase: Phase 2
Study type: Interventional

To explore the safety, tolerability, pharmacokinetics and efficacy of ABT-SLV187 in advanced Parkinson's disease (PD) patients with severe motor complications. The complications of medical devices for the naso-jejunum (NJ) infusion system of ABT-SLV187 will also be investigated.

NCT ID: NCT00660673 Completed - Clinical trials for Advanced Parkinson's Disease

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

Start date: November 13, 2009
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to provide continued access to levodopa-carbidopa intestinal gel (LCIG), to participants who have already participated in an open-label efficacy and safety study with the same treatment (Study S187.3.003 [NCT00360568] or Study S187.3.004 [NCT00335153]).

NCT ID: NCT00660387 Completed - Clinical trials for Advanced Parkinson's Disease

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

Start date: December 2009
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to demonstrate the superiority of levodopa - carbidopa intestinal gel over treatment with optimized oral levodopa/carbidopa during 12 weeks.

NCT ID: NCT00357994 Completed - Clinical trials for Advanced Parkinson's Disease

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

Start date: January 2009
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to demonstrate the superiority of levodopa - carbidopa intestinal gel over treatment with optimized oral levodopa/carbidopa during 12 weeks.

NCT ID: NCT00335153 Completed - Clinical trials for Advanced Parkinson's Disease

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

Start date: January 2008
Phase: Phase 3
Study type: Interventional

The primary objective of this study will be to provide further evidence of the long-term safety and tolerability of levodopa-carbidopa intestinal gel (Duodopa®) over 12-months in participants with advanced Parkinson's disease (PD) and severe motor fluctuations.